Neuroimaging biomarkers are critical indicators gleaned from brain images, offering insights into neurological disorders, cognitive functions, and treatment responses. These measurable characteristics, categorized into structural and functional biomarkers, provide objective evidence of brain anatomy, function, and connectivity. Structural biomarkers, discerned through techniques like magnetic resonance imaging (MRI), unveil anomalies in brain structure linked to conditions such as Alzheimer's disease, multiple sclerosis, and traumatic brain injury. They aid in identifying structural changes, guiding disease prognosis and treatment evaluation. Conversely, functional biomarkers assess brain activity or connectivity patterns tied to specific cognitive functions or clinical symptoms. Employing techniques like functional MRI (fMRI) and positron emission tomography (PET), aberrant neural activity associated with depression, schizophrenia, or epilepsy can be detected. Analysis of brain activation or connectivity patterns facilitates distinguishing between clinical populations and predicting treatment outcomes. These biomarkers are invaluable in drug development and clinical trials, offering objective measures of treatment efficacy and safety. By assessing the impact of novel therapies on brain structure or function, researchers can identify promising treatments and expedite the drug development process. Beyond clinical applications, neuroimaging biomarkers deepen our understanding of neurological disorders and cognitive processes. By elucidating neural correlates, researchers refine diagnostic criteria, develop targeted interventions, and enhance patient outcomes.
Title : Novel important cellular responses, signaling mechanisms and therapeutic options in vascular dementia
Yong Xiao Wang, Albany Medical College, United States
Title : TBI updates in 2025
Jonathan Eskenazi, Cedars Sinai / UCLA, United States
Title : A case of vile vindictive primary CNS vasculitis
George Diaz, Memorial Healthcare Systems, United States
Title : Non-pharmacological strategies to counteract oxaliplatin toxicity: Protective effects of vagal nerve stimulation and resistance training on neuropathy, motor dysfunction, and muscle atrophy
Ricardo Aparecido Baptista Nucci, Hospital Sirio-Libanes, Brazil
Title : Synapticare: Integrating sleep data and tau biomarkers to assess depression severity
Medha Menon, John Foster Dulles HS, United States
Title : How have we eliminated infection: From the bone to brain?
Thomas J Webster, Interstellar Therapeutics, United States